Drug discontinuation: Atazanavir Sulfate; Cobicistat Tablet (EVOTAZ)
FDA lists 1 presentation as To Be Discontinued. Companies: Bristol Myers Squibb Co..
- Published by source
- 2025-11-03
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Bristol Myers Squibb Co.
- Products
- Atazanavir Sulfate; Cobicistat Tablet EVOTAZ
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2025-11-03
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #981 | new | 2026-10-22 | 899603ac3f02…8d9d5e | 001f623af702…89cb9e |
Chain head: #1076 8ad5adc30b9b…88ce20